Poseida Therapeutics Growth, Revenue, Number of Employees and Funding
Revenue & Financials
- Poseida Therapeutics received $30.0M in venture funding in April 2018. 0
- Poseida Therapeutics's total funding is $226.5M.
- Poseida Therapeutics has 63 Employees.
- Poseida Therapeutics grew their employee count by 43% last year.
- Poseida Therapeutics currently has 11 job openings.
What Is Poseida Therapeutics?
Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac DNA Modification System, TAL-CLOVER and Cas-CLOVER site-specific nucleases, and Footprint-Free Gene Editing (FFGE). For more information, visit www.poseida.com.keywords:Automotive,Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$23.9M||166||8%|
|Full Spectrum A...||$5.7M||39||5%|
Poseida Therapeutics News
J. Keith Joung (J.K.J.) has financial interests in Beam Therapeutics, ... EpiLogic Therapeutics, Pairwise Plants, Poseida Therapeutics, and
13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene
Poseida Therapeutics, which is testing CAR-T cell therapies for blood-borne and solid tumor cancers, has laid the groundwork for an initial
Poseida Therapeutics Funding
|2015-12-17||$30.0M||A||Malin Corporation plc||Article|
Poseida Therapeutics Executive Hires
|2017-01-04||Debra Gessner||VP Regulatory Affairs||Article|
|2018-02-06||Martin Giedlin||Vice President, Technical Operations||Article|
|2018-03-01||Mark Gergen||chief business officer and chief financial officer.||Article|
|2018-10-10||Marcy Graham||Vice President, Corporate Affairs||Article|